Adding memantine to rivastigmine therapy in patients with mild-to-moderate Alzheimer's disease: Results of a 12-week, open-label pilot study

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 8, Issue 5, 2006, Pages 258-263

  Riepe, Matthias W ^a,b   Adler, Georg ^c   Ibach, Bernd ^d   Weinkauf, Birgit ^e   Gunay, Ibrahim ^f   Tracik, Ferenc ^e  

^a UNIVERSITY OF ULM   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^d UNIVERSITY OF REGENSBURG   (Germany)

^e Winicker Norimed   (Germany)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RIVASTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DEMENTIA; DEMOGRAPHY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERANCE; EAR DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; INJURY; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MENTAL DISEASE; NEUROLOGIC DISEASE; PILOT STUDY; RESPIRATORY TRACT DISEASE; SCORING SYSTEM; SYNCOPE; THORAX DISEASE; VASCULAR DISEASE;

EID: 33749534681     PISSN: 15235998     EISSN: None     Source Type: Journal    
DOI: 10.4088/pcc.v08n0501     Document Type: Article

References (31)

1. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA 1989;262:2551-2556
2. Hebert LE, Scherr PA, Beckett LA, et al. Age-specific incidence of Alzheimer's disease in a community population. JAMA 1995;273:1354-1359
3. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998;88:1337-1342
4. Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry 2003;11:131-145
5. Lanctot KL, Herrmann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 2003;169:557-564
6. Darreh-Shori T, Almkvist O, Guan ZZ, et al. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 2002;59:563-572
7. Rosler M. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int J Clin Pract Suppl 2002;127:20-36
8. Areosa SA, Sherriff F. Memantine for dementia. Cochrane Database Syst Rev 2003;3:CD003154
9. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999;14:135-146
10. Ruther E, Glaser A, Bleich S, et al. A prospective PMS study to validate the sensitivity for change of the D-scale in advanced stages of dementia using the NMDA-antagonist memantine. Pharmacopsychiatry 2000;33:103-108
11. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-1341
12. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: a review of preclinical data. Neuropharmacology 1999;38:735-767
13. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317-324
14. The World Medical Association. The Declaration of Helsinki. Available at: http://www.wma.net/e/policy/b3.htm. Accessibility verified July 6, 2006
15. The Commission of the European Communities. Commission Directive 2005/28/EC of 8 April 2005 laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorisation of the manufacturing or importation of such products. The Official Journal of the European Union. April 9, 2005. Available at: http://pharmacos.eudra.org/F2/eudralex/vol-1/DIR_2005_28/ DIR_2005_28_EN.pdf. Accessibility verified July 6, 2006
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
17. Folstein ME, Folstein SE, McHugh PR. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198
18. Rosen WG, Mobs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364
19. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease: The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(suppl 2):S33-S39
20. Reisberg B, Ferris S, de Leon M, et al. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-1139
21. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Psychopharmacol 1998;1:55-65
22. Bentue-Ferrer D, Tribut O, Polard E, et al. Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs 2003;17:947-963
23. Nordberg A, Svensson AL. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Saf 1998;19:465-480
24. Farlow MR, Lilly ML, ENA713 B352 Study Group. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years. BMC Geriatr 2005;5:3
25. Aupperle PM, Koumaras B, Chen M, et al. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study. Curr Med Res Opin 2004;20:1605-1612
26. Beusterien KM, Thomas SK, Gause D, et al. Impact of rivastigmine use on the risk of nursing home placement in a US sample. CNS Drugs 2004;18:1143-1148
27. Finkel SI. Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease. Clin Ther 2004;26:980-990
28. Desai AK, Grossberg GT, Sheth DN. Activities of daily living in patients with dementia: clinical relevance, methods of assessment and effects of treatment. CNS Drugs 2004;18:853-875
29. Feldman HH, Van Baelen B, Kavanagh SM, et al. Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: a 12-month analysis. Alzheimer Dis Assoc Disord 2005;19:29-36
30. Lopez OL, Becker JT, Saxton J, et al. Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition. J Am Geriatr Soc 2005;53:83-87
31. Passmore P, Patterson C. Acetylcholinesterase inhibitors: cognition and function. CPD Bull Old Age Psychiatry 2001;2:63-70. Available at: http://www.rila.co.uk/issues/full/download/ d0e47b8bbf596cbd8b0c9ace61a09fa0361180.pdf. Accessibility verified Sept 6, 2005